Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 565.90M |
| Revenue (ttm) | 57.47M |
| Net Income (ttm) | -183.97M |
| Shares Out | 46.54M |
| EPS (ttm) | -3.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,765 |
| Average Volume | 249,082 |
| Open | 12.42 |
| Previous Close | 12.10 |
| Day's Range | 12.16 - 12.68 |
| 52-Week Range | 9.31 - 19.64 |
| Beta | n/a |
| RSI | 23.93 |
| Earnings Date | Apr 16, 2026 |
About Cinclus Pharma Holding AB
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and... [Read more]
Full Company ProfileFinancial Performance
In 2025, Cinclus Pharma Holding AB's revenue was 57.47 million, an increase of 1154.80% compared to the previous year's 4.58 million. Losses were -183.97 million, 9.49% more than in 2024.
Financial StatementsNews
Cinclus Pharma Holding AB Earnings Call Transcript: Q4 2025
Linaprazan glurate advances through phase III with strong financial backing and global partnerships, targeting blockbuster potential in severe erosive GERD. Revenue growth is driven by licensing deals, while regulatory and clinical milestones position the product for 2026 launches.
Cinclus Pharma Holding AB Transcript: KOL Event
Linaprazan glurate is poised to address major unmet needs in severe erosive GERD, offering best-in-class acid control and rapid symptom relief. The large, dynamic market supports strong commercial potential, but success will require focused marketing and differentiation among specialists.
Cinclus Pharma Holding AB Earnings Call Transcript: Q3 2025
Phase III trial for linaprazan glurate is underway with strong recruitment and positive regulatory feedback. Financials show increased R&D investment and a solid cash runway into 2027, while global PCAB market momentum supports future commercial prospects.
Cinclus Pharma Holding AB Transcript: Stifel 2025 Healthcare Conference
Linaprazan glurate, a next-generation PCAB, is in Phase III trials targeting severe GERD patients with unmet needs, aiming for premium pricing and specialist market focus. Strong IP, a major European partnership, and a U.S. launch planned for 2029-2030 underpin the strategy.
Cinclus Pharma Holding AB Earnings Call Transcript: Q2 2025
Secured a EUR 220 million Zentiva partnership for Linaprazan glurate in Europe, with phase III trial preparations complete and imminent start. Cash position remains strong at SEK 589 million, and U.S. commercialization rights are retained for future value creation.
Cinclus Pharma Holding AB Transcript: Investor Update
A strategic partnership with Zentiva secures up to EUR 220 million for linaprazan glurate's European commercialization, with strong royalty terms and a 10-year exclusivity. Zentiva's pan-European reach and specialty pharma focus support targeting severe GERD patients and may accelerate clinical development.
Cinclus Pharma Holding AB Earnings Call Transcript: Q1 2025
Lead asset linaprazan glurate advances to Phase III after strong Phase II results, targeting severe eGERD with best-in-class potential and robust patent protection. Cash reserves support operations through 2026, with premium pricing and dynamic market opportunities anticipated.
Cinclus Pharma Holding AB Earnings Call Transcript: Q4 2024
PCABs are rapidly gaining market share globally, with linaprazan glurate now approved in China and pivotal Phase III trials set for the U.S. and Europe. Financials remain strong after a major share issue, supporting operations through key 2026 milestones.
Cinclus Pharma Holding AB Earnings Call Transcript: Q3 2024
Development of linaprazan glarate advances with phase III trial preparations on schedule and strong IP protection extending beyond 2040. Cash reserves remain robust post-IPO, with further financing planned after key clinical milestones.
Cinclus Pharma Holding AB Earnings Call Transcript: Q2 2024
Strong cash position after a SEK 750 million IPO supports phase III development of a next-gen P-CAB for severe eGERD, with first patient expected in 2025 and key readouts in 2026. Patent protection extends to 2042, and China approval could bring milestone payments by year-end.